Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: Initial experience

Radiology

Volumn 248, Issue 3, 2008, Pages 917-924

  Okuda, Shigeo ^a   Oshio, Koichi ^a   Shinmoto, Hiroshi ^b   Tanimoto, Akihiro ^a   Asada, Hironori ^a   Fujii, Takuma ^a   Yoshimura, Yasunori ^a   Kuribayashi, Sachio ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; LEUPRORELIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG EFFICACY; FEMALE; HUMAN; INFORMED CONSENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STUDENT T TEST; UTERUS MYOMA; ALGORITHM; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DRUG POTENTIATION; LEIOMYOMA; METHODOLOGY; PILOT STUDY; PROGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UTERUS CANCER;

ADULT; ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LEIOMYOMA; LEUPROLIDE; MAGNETIC RESONANCE IMAGING; PILOT PROJECTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 51549112351     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2483071288     Document Type: Article

References (39)

1. Buttram VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 1981;36:433-445.
2. Cura M, Cura A, Bugnone A. Role of magnetic resonance imaging in patient selection for uterine artery embolization. Acta Radiol 2006;47:1105-1114.
3. Pinto I, Chimeno P, Romo A, et al. Uterine fibroids: uterine artery embolization versus abdominal hysterectomy for treatment - a prospective, randomized, and controlled clinical trial. Radiology 2003;226:425-431.
4. Tempany CM, Stewart EA, McDannold N, et al. MR imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasibility study. Radiology 2003;226:897-905.
5. McDannold N, Tempany CM, Fennessy FM, et al. Uterine leiomyomas: MR imaging-based thermometry and thermal dosimetry during focused ultrasound thermal ablation. Radiology 2006;240:263-272.
6. Ripps BA, VanGilder K, Minhas B, et al. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. J Reprod Med 2003;48:761-766.
7. Kurabayashi T, Fujimaki T, Yasuda M, et al. Time-course of vertebral and femoral bone loss in rats administered gonadotrophin-releasing hormone agonist. J Endocrinol 1993;138:115-125.
8. Matta WH, Shaw RW, Nye M. Long-term follow up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br J Obstet Gynaecol 1989;96:200-206.
9. Friedman AJ, Hoffman DI, Comite F, et al; for the Leuprolide Study Group. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. Obstet Gynecol 1991;77:720-725.
10. Kiltz RJ, Rutgers J, Phillips J, et al. Absence of a dose-response effect of leuprolide acetate on leiomyomata uteri size. Fertil Steril 1994;61:1021-1026.
11. Oguchi O, Mori A, Kobayashi Y, et al. Prediction of histopathologic features and proliferative activity of uterine leiomyoma by magnetic resonance imaging prior to GnRh analogue therapy: correlation between T2-weighted images and effect of GnRH analogue. J Obstet Gynaecol 1995;21:107-117.
12. Matsuno Y, Yamashita Y, Takahashi M, et al. Predicting the effect of gonadotropin releasing hormone (GnRH) analogue treatment on uterine leiomyomas based on MR imaging. Acta Radiol 1999;40:656-662.
13. Takahashi K, Okada M, Imaoka I, et al. Value of magnetic resonance imaging in predicting efficacy of GnRH analogue treatment for uterine leiomyoma. Hum Reprod 2001;16:1989-1994.
14. Furui T, Imai A, Takagi A, et al. Differential efficacy of gonadotropin-releasing hormone (GnRH) agonist treatment on pedunculated and degenerated myomas: a retrospective study of 630 women. J Obstet Gynaecol 2000;20:504-506.
15. Maeda M, Itoh S, Kimura H, et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 1993;189:233-238.
16. Miyati T, Banno T, Mase M, et al. Dual dynamic contrast-enhanced MR imaging. J Magn Reson Imaging 1997;7:230-235.
17. Kuperman VY, Alley MT. Differentiation between the effects of T1 and T2* shortening in contrast-enhanced MRI of the breast. J Magn Reson Imaging 1999;9:172-176.
18. Uematsu H, Maeda M, Sadato N, et al. Vascular permeability: quantitative measurement with double-echo dynamic MR imaging - theory and clinical application. Radiology 2000;214:912-917.
19. Kosakai N, Uematsu H, Kimura H, et al. The assessment of the vascularity of uterine leiomyomas using double-echo dynamic perfusion MRI: correlation with histopathology [abstr]. In: Proceedings of the 13th Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2005;1936.
20. Lankester KJ, Taylor JN, Stirling JJ, et al. Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging 2007;25:796-805.
21. Watanabe Y, Nakamura G, Matsuguchi H, et al. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil Steril 1992;58:66-71.
22. Buadu LD, Murakami J, Murayama S, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996;200:639-649.
23. Verstraete KL, De Deene Y, Roels H, et al. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging - parametric "first-pass" images depict tissue vascularization and perfusion. Radiology 1994;192:835-843.
24. Hawighorst H, Knapstein PG, Weikel W, et al. Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 1997;57:4777-4786.
25. Li W, Brophy DP, Chen Q, et al. Semiquantitative assessment of uterine perfusion using first pass dynamic contrast-enhanced MR imaging for patients treated with uterine fibroid embolization. J Magn Reson Imaging 2000;12:1004-1008.
26. Boxerman JL, Hamberg LM, Rosen BR, et al. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555-566.
27. van Osch MJ, Vonken EJ, Viergever MA, et al. Measuring the arterial input function with gradient echo sequences. Magn Reson Med 2003;49:1067-1076.
28. Anania CA, Stewart EA, Quade BJ, et al. Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding. Mol Hum Reprod 1997;3:685-691.
29. Di Lieto A, De Falco M, Staibano S, et al. Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) in uterine leiomyomas. Int J Gynecol Pathol 2003;22:353-358.
30. Di Lieto A, De Falco M, Pollio F, et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig 2005;12:123-128.
31. Demopoulos RI, Jones KY, Mittal KR, Vamvakas EC. Histology of leiomyomata in patients treated with leuprolide acetate. Int J Gynecol Pathol 1997;16:131-137.
32. Crow J, Gardner RL, McSweeney G, et al. Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin. Int J Gynecol Pathol 1995;14:235-242.
33. Rutgers JL, Spong CY, Sinow R, et al. Leuprolide acetate treatment and myoma arterial size. Obstet Gynecol 1995;86:386-388.
34. Gokdeniz R, Ozen S, Mizrak B, et al. GnRH agonist decreases endothelial nitric oxide synthase (eNOS) expression in leiomyoma. Int J Gynaecol Obstet 2000;70:347-352.
35. Aleem FA, Predanic M. The hemodynamic effect of GnRH agonist therapy on uterine leiomyoma vascularity: a prospective study using transvaginal color Doppler sonography. Gynecol Endocrinol 1995;9:253-258.
36. Goodwin SC, Bradley LD, Lipman JC, et al. Uterine artery embolization versus myomectomy: a multicenter comparative study. Fertil Steril 2006;85:14-21.
37. Stewart EA, Gostout B, Rabinovici J, et al. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol 2007;110:279-287.
38. Ghezzi F, Cromi A, Bergamini V, et al. Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas. Surg Endosc 2007;21:2081-2085.
39. Abulafia O, Kleinhaus K, Levi G, et al. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma. Gynecol Obstet Invest 2001;52:108-113.